mRNA疫苗脂质纳米颗粒递送系统的专利发展状况分析

doi:10.5246/jcps.2023.02.009

中国药学(英文版) ›› 2023, Vol. 32 ›› Issue (2): 112-121.DOI: 10.5246/jcps.2023.02.009

• 【药事管理与临床药学专栏】 • 上一篇下一篇

mRNA疫苗脂质纳米颗粒递送系统的专利发展状况分析

葛嘉¹^,^#, 陈龙飞¹^,^#, 聂小燕², 陈敬²^,^*()

1. 国家知识产权局专利局复审和无效审查部, 北京 100088
2. 北京大学医学部药学院药事管理与临床药学系, 北京 100191

收稿日期:2022-10-21 修回日期:2022-11-12 接受日期:2022-11-30 出版日期:2023-02-28 发布日期:2023-02-28
通讯作者: 陈敬
作者简介:
+ Tel.: +86-10-82805879, E-mail: jingchen@bjmu.edu.cn

Analysis of patent development status of lipid nanoparticle delivery system for mRNA vaccines

Jia Ge¹^,^#, Longfei Chen¹^,^#, Xiaoyan Nie², Jing Chen²^,^*()

1 Reexamination and Invalidation Department of the Patent Office, China National Intellectual Property Administration (CNIPA), Beijing 100088, China
2 Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Peking University Health Science Center, Beijing 100191, China

Received:2022-10-21 Revised:2022-11-12 Accepted:2022-11-30 Online:2023-02-28 Published:2023-02-28
Contact: Jing Chen
About author:
# Jia Ge and Longfei Chen contributed equally to this work.

摘要/Abstract

摘要：

本文分析了全球范围内mRNA疫苗脂质纳米颗粒递送技术的专利申请现状和进展, 深入挖掘该领域的技术发展动态, 分析对比国内外申请人的相关情况, 以期为国内医药领域从事mRNA递送系统研究人员提供参考与启示。

关键词: mRNA疫苗, LNP, 专利分析

Abstract:

In the present study, we analyzed the patent application status and progress of lipid nanoparticle (LNP) delivery technology for mRNA vaccines on a global scale, focusing on the technological development dynamics. Moreover, we compared the relevant situation of domestic and foreign applicants, aiming to provide references for researchers engaged in mRNA vaccine delivery systems in the domestic pharmaceutical field.

Key words: mRNA vaccine, LNP, Patent analysis

Supporting:

葛嘉, 陈龙飞, 聂小燕, 陈敬. mRNA疫苗脂质纳米颗粒递送系统的专利发展状况分析[J]. 中国药学(英文版), 2023, 32(2): 112-121.

Jia Ge, Longfei Chen, Xiaoyan Nie, Jing Chen. Analysis of patent development status of lipid nanoparticle delivery system for mRNA vaccines[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(2): 112-121.

图/表 11

Figure 1. Annual trend of patent filings for LNP delivery-mRNA vaccines.

Figure 2. Geographical distribution of patent applications.

Figure 3. Main patent applicants for LNP delivery-mRNA vaccine of the world. a, Massachusetts Institute of Technology; b, The Trustee of the University of Pennsylvania.

Figure 4. Patent filing trend of LNP delivery-mRNA vaccine in China.

Figure 5. Country distribution of patent applicants for the LNP delivery-mRNA vaccine in China.

Figure 6. Main applicants of the LNP delivery-mRNA vaccine.

Figure 7. Main patentees of the LNP delivery-mRNA vaccine.

Table 1. Chinese patentees of LNP delivery-mRNA vaccine.

Figure 8. Cationic lipid compound of patent CN20211052536.2.

Figure 9. Cationic lipid compound of patent CN202110525389.1.

Figure 10. Lipid compound of patent CN20211061744.5.

参考文献 10

[1]	Li, M.; Wang, H.; Tian, L.; Pang, Z.; Yang, Q.; Huang, T.; Fan, J.; Song, L.; Tong, Y.; Fan, H. COVID-19 vaccine development: milestones, lessons and prospects. Signal. Transduct. Target. Ther. 2022, 7, 146.
[2]	Frost & Sullivan report, Research Report on the Status Quo and Future Development of the Nucleic Acid Drug Market, May 20^th, 2022.
[3]	Hou, X.C.; Zaks, T.; Langer, R.; Dong, Y.Z. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 2021, 6, 1078–1094.
[4]	Yang, J. Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis. Expert. Rev. Clin. Pharmacol. 2019, 12, 95–99.
[5]	Bureau de l’Économie et du Commerce de l’Ambassade de la République Populaire de Chine en République Française, Sanofi acquires Translate BIO for $3.2 billion, http://www.mofcom.gov.cn/article/i/jyjl/m/202108/ 20210803184559.shtml, August 06^th, 2021.
[6]	Liu, X.Q.; Li, Y.H.; Wang, Z.F.; Cao, S.C.; Huang, W.J.; Yuan, L.; Huang, Y.J.; Zheng, Y.; Chen, J.J.; Ying, B.; Xiang, Z.Y.; Shi, J.; Zhao, J.C.; Huang, Z.; Qin, C.F. Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults. Cell Res. 2022, 32, 777–780.
[7]	China became the third country to have approved a mRNA vaccine for marketing, https://www.163.com/dy/article/HIMGUIQQ0552ADWT.html, October 02^nd, 2022.
[8]	Shores, D.; Vivian, T.; Sheena, W. mRNA Patent and Competitive Landscape: 2021 year in Review and 2022 outlook, https://www.rfemerge.com/2022/01/03/mrna-patent-and-competitive-landscape-2021-in-review-and-2022-outlook/, January 3^rd, 2022.
[9]	Xin, X.B. Overview of current mRNA-related patent litigation in the United States, Frontiers of Intellectual Property Public Account, https://mp.weixin.qq.com/s/uXDyOlMRszFGserD0MHXOg, September 14^th, 2022.
[10]	LPP Delivery Platform, Siwei (Shanghai) Biotechnology Co., Ltd. official website, http://www.stemirna.com/lpp/index.aspx.

mRNA疫苗脂质纳米颗粒递送系统的专利发展状况分析

Analysis of patent development status of lipid nanoparticle delivery system for mRNA vaccines

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 11

参考文献 10

相关文章 0

编辑推荐

Metrics

本文评价